🇺🇸 human chorionic gonadotropin in United States

154 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 154

Most-reported reactions

1. Ovarian Hyperstimulation Syndrome — 36 reports (23.38%)
2. Maternal Exposure During Pregnancy — 22 reports (14.29%)
3. Off Label Use — 20 reports (12.99%)
4. Abortion Spontaneous — 17 reports (11.04%)
5. Drug Ineffective — 14 reports (9.09%)
6. Product Use In Unapproved Indication — 14 reports (9.09%)
7. Maternal Exposure Before Pregnancy — 13 reports (8.44%)
8. Abdominal Distension — 6 reports (3.9%)
9. Caesarean Section — 6 reports (3.9%)
10. Dizziness — 6 reports (3.9%)

Source database →

Frequently asked questions

Is human chorionic gonadotropin approved in United States?

human chorionic gonadotropin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for human chorionic gonadotropin in United States?

Martin Blomberg Jensen is the originator. The local marketing authorisation holder may differ — check the official source linked above.